Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?

被引：23

作者：

Marian, Calin O. ^{[1
]}

Shay, Jerry W. ^{[1
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2009年 / 1792卷 / 04期

关键词：

Prostate; Telomere; Telomerase; Tumor-initiating cell; GRN163L; CANCER STEM-CELLS; METASTATIC PROSTATE; PROSPECTIVE IDENTIFICATION; INTRAEPITHELIAL NEOPLASIA; HUMAN FIBROBLASTS; PROGENITOR CELLS; NEEDLE-BIOPSY; ANDROGEN; DNA; OLIGONUCLEOTIDE;

D O I：

10.1016/j.bbadis.2009.02.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：289 / 296

页数：8

共 79 条

[1] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[2]

Aragon-Ching Jeanny B, 2007, Cancer Ther, V5A, P151

[3]

Asai A, 2003, CANCER RES, V63, P3931

[4] Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Fisher, G. ;

Kovacs, G. ;

Flohr, P. ;

Berney, D. ;

Foster, C. S. ;

Fletcher, A. ;

Gerald, W. L. ;

Moller, H. ;

Reuter, V. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

ONCOGENE, 2008, 27 (03) :253-263

[5] Mechanism of telomerase induction during T cell activation [J].

Bodnar, AG ;

Kim, NW ;

Effros, RB ;

Chiu, CP .

EXPERIMENTAL CELL RESEARCH, 1996, 228 (01) :58-64

[6] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].

Bonnet, D ;

Dick, JE .

NATURE MEDICINE, 1997, 3 (07) :730-737

[7] Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer [J].

Brunsvig, Paal F. ;

Aamdal, Steinar ;

Gjertsen, Marianne K. ;

Kvalheim, Gunnar ;

Markowski-Grimsrud, Carrie J. ;

Sve, Ingunn ;

Dyrhaug, Marianne ;

Trachsel, Sissel ;

Moller, Mona ;

Eriksen, Jon A. ;

Gaudernack, Gustav .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (12) :1553-1564

[8] Telomerase regulation during entry into the cell cycle in normal human T cells [J].

Buchkovich, KJ ;

Greider, CW .

MOLECULAR BIOLOGY OF THE CELL, 1996, 7 (09) :1443-1454

[9] The bone microenvironment in metastasis; what is special about bone? [J].

Bussard, Karen M. ;

Gay, Carol V. ;

Mastro, Andrea M. .

CANCER AND METASTASIS REVIEWS, 2008, 27 (01) :41-55

[10] Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model [J].

Canales, BK ;

Li, YM ;

Thompson, MG ;

Gleason, JM ;

Chen, Z ;

Malaeb, B ;

Corey, DR ;

Herbert, BS ;

Shay, JW ;

Koeneman, KS .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (02) :141-151

← 1 2 3 4 5 6 7 8 →